Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2010

01-08-2010 | Case Report

Minimal change nephrotic syndrome in a patient with strongyloidiasis

Authors: Mieko Miyazaki, Masahito Tamura, Narutoshi Kabashima, Ryota Serino, Tatsuya Shibata, Tetsu Miyamoto, Yumi Furuno, Tetsuo Nishio, Jiro Ohara, Toshihiro Sakurai, Yutaka Otsuji

Published in: Clinical and Experimental Nephrology | Issue 4/2010

Login to get access

Abstract

Strongyloidiasis, a chronic infection caused by the intestinal parasite Strongyloides stercoralis, is prevalent in the Nansei Islands of Japan. Here, we report our findings on a case of strongyloidiasis complicated with steroid-resistant minimal change nephrotic syndrome in a 69-year-old male resident of Fukuoka Prefecture who had lived in Yakushima, one of the Nansei Islands, until age 15. In October 2006, he developed proteinuria and edema, and was diagnosed with minimal change nephrotic syndrome on the basis of the renal biopsy findings. Following treatment with prednisolone, the level of proteinuria decreased to 0.29 g/day by day 35. However, 5 days later (day 40), the patient developed persistent watery diarrhea and vomiting, leading to dehydration and malnutrition. Pneumonia and bacterial meningitis subsequently developed (day 146); filarial (infectious-type) and rhabditiform (noninfectious-type) S. stercoralis larvae were detected for the first time in the patient’s sputum, gastric juice, feces, and urine. Although treatment with ivermectin was started immediately and the parasitosis responded to the treatment, the patient died of sepsis. Consequently, although strongyloidiasis is a rare infection except in endemic regions, it is essential to consider the possibility of this disease and begin treatment early for patients who have lived in endemic areas and who complain of unexplained diarrhea during steroid-induced or other immunosuppression.
Literature
1.
go back to reference Fardet L, Genereau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54:18–27.CrossRefPubMed Fardet L, Genereau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect. 2007;54:18–27.CrossRefPubMed
2.
go back to reference Saito A. Strongyloidiasis—progress in its diagnosis and treatment. Nippon Naika Gakkai Zasshi. 2003;92:399–403. Saito A. Strongyloidiasis—progress in its diagnosis and treatment. Nippon Naika Gakkai Zasshi. 2003;92:399–403.
3.
go back to reference Hsieh YP, Wen YK, Chen ML. Minimal change nephrotic syndrome in association with strongyloidiasis. Clin Nephrol. 2006;66:459–63.PubMed Hsieh YP, Wen YK, Chen ML. Minimal change nephrotic syndrome in association with strongyloidiasis. Clin Nephrol. 2006;66:459–63.PubMed
4.
go back to reference Morimoto J, Kaneoka H, Sasatomi Y, Sato YN, Murata T, Ogahara S, et al. Disseminated strongyloidiasis in nephrotic syndrome. Clin Nephrol. 2002;57:398–401.PubMed Morimoto J, Kaneoka H, Sasatomi Y, Sato YN, Murata T, Ogahara S, et al. Disseminated strongyloidiasis in nephrotic syndrome. Clin Nephrol. 2002;57:398–401.PubMed
5.
go back to reference Sathe PA, Madiwale CV. Strongyloidiasis hyperinfection in a patient with membranoproliferative glomerulonephritis. J Postgrad Med. 2006;52:221–2.PubMed Sathe PA, Madiwale CV. Strongyloidiasis hyperinfection in a patient with membranoproliferative glomerulonephritis. J Postgrad Med. 2006;52:221–2.PubMed
6.
go back to reference Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis. 2006;25:14–8.CrossRefPubMed Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis. 2006;25:14–8.CrossRefPubMed
7.
go back to reference Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol. 2005;12:680–2.PubMed Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol. 2005;12:680–2.PubMed
8.
go back to reference Mitsunaga M, Miyauchi N, Akiyama Y, Saima S. A case of strongyloidiasis hyperinfection during oral corticosteroid therapy associated with a nephrotic patient infected with HTLV-1. Nippon Ronen Igakkai Zasshi. 2003;40:397–401.CrossRefPubMed Mitsunaga M, Miyauchi N, Akiyama Y, Saima S. A case of strongyloidiasis hyperinfection during oral corticosteroid therapy associated with a nephrotic patient infected with HTLV-1. Nippon Ronen Igakkai Zasshi. 2003;40:397–401.CrossRefPubMed
9.
go back to reference Yee YK, Lam CS, Yung CY, Que TL, Kwan TH, Au TC, et al. Strongyloidiasis as a possible cause of nephrotic syndrome. Am J Kidney Dis. 1999;33:E4.CrossRefPubMed Yee YK, Lam CS, Yung CY, Que TL, Kwan TH, Au TC, et al. Strongyloidiasis as a possible cause of nephrotic syndrome. Am J Kidney Dis. 1999;33:E4.CrossRefPubMed
10.
go back to reference Wong TY, Szeto CC, Lai FF, Mak CK, Li PK. Nephrotic syndrome in strongyloidiasis: remission after eradication with anthelmintic agents. Nephron. 1998;79:333–6.CrossRefPubMed Wong TY, Szeto CC, Lai FF, Mak CK, Li PK. Nephrotic syndrome in strongyloidiasis: remission after eradication with anthelmintic agents. Nephron. 1998;79:333–6.CrossRefPubMed
11.
go back to reference Mori S, Konishi T, Matsuoka K, Deguchi M, Ohta M, Mizuno O, et al. Strongyloidiasis associated with nephrotic syndrome. Intern Med. 1998;37:606–10.CrossRefPubMed Mori S, Konishi T, Matsuoka K, Deguchi M, Ohta M, Mizuno O, et al. Strongyloidiasis associated with nephrotic syndrome. Intern Med. 1998;37:606–10.CrossRefPubMed
12.
go back to reference Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med. 1966;275:1093–6.CrossRefPubMed Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med. 1966;275:1093–6.CrossRefPubMed
14.
go back to reference Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy. 2006;4:8.CrossRefPubMed Vadlamudi RS, Chi DS, Krishnaswamy G. Intestinal strongyloidiasis and hyperinfection syndrome. Clin Mol Allergy. 2006;4:8.CrossRefPubMed
15.
go back to reference Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992–2001. Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992–2001.
16.
go back to reference Boonpucknavig V, Soontornniyomkij V. Pathology of renal diseases in the tropics. Semin Nephrol. 2003;23:88–106.CrossRefPubMed Boonpucknavig V, Soontornniyomkij V. Pathology of renal diseases in the tropics. Semin Nephrol. 2003;23:88–106.CrossRefPubMed
17.
go back to reference Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150:2379–84. Simon DI, Brosius FC, Rothstein DM. Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1990;150:2379–84.
18.
19.
go back to reference Copelovitch L, Sam Ol O, Taraquinio S, Chanpheaktra N. Childhood nephrotic syndrome in Cambodia: an association with gastrointestinal parasites. J Pediatr. 2010;156:76–81.CrossRefPubMed Copelovitch L, Sam Ol O, Taraquinio S, Chanpheaktra N. Childhood nephrotic syndrome in Cambodia: an association with gastrointestinal parasites. J Pediatr. 2010;156:76–81.CrossRefPubMed
20.
go back to reference Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991;44:243–5.CrossRefPubMed Gill DS, Fonseca VA, Barradas MA, Balliod R, Moorhead JF, Dandona P. Plasma histamine in patients with chronic renal failure and nephrotic syndrome. J Clin Pathol. 1991;44:243–5.CrossRefPubMed
21.
go back to reference Bheekha-Escura R, MacGlashan DW, Langdon JM, MacDonald SM. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14–3D10. Blood. 2000;96:2191–8.PubMed Bheekha-Escura R, MacGlashan DW, Langdon JM, MacDonald SM. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14–3D10. Blood. 2000;96:2191–8.PubMed
22.
go back to reference Toyabe S, Kaneko U, Hara M, Uchiyama M. Expression of immunoglobulin E-dependent histamine-releasing factor in idiopathic nephrotic syndrome of childhood. Clin Exp Immunol. 2005;142:162–6.CrossRefPubMed Toyabe S, Kaneko U, Hara M, Uchiyama M. Expression of immunoglobulin E-dependent histamine-releasing factor in idiopathic nephrotic syndrome of childhood. Clin Exp Immunol. 2005;142:162–6.CrossRefPubMed
23.
go back to reference Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez-Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. 2004;5:2615–9.CrossRefPubMed Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sanchez-Sanchez P, Matogo-Oyana J, Rodriguez-Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother. 2004;5:2615–9.CrossRefPubMed
Metadata
Title
Minimal change nephrotic syndrome in a patient with strongyloidiasis
Authors
Mieko Miyazaki
Masahito Tamura
Narutoshi Kabashima
Ryota Serino
Tatsuya Shibata
Tetsu Miyamoto
Yumi Furuno
Tetsuo Nishio
Jiro Ohara
Toshihiro Sakurai
Yutaka Otsuji
Publication date
01-08-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-010-0273-4

Other articles of this Issue 4/2010

Clinical and Experimental Nephrology 4/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.